Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a ...

Bristol-Myers Squibb, in partnership with K36 Therapeutics, updated progress on their Phase 1 trial of KTX-1001 for relapsed ...

Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-risk sexual ...

Bristol Myers Squibb outperformed major indexes, closing 1.32% higher at $47.66, while peers lagged. The company’s stock ...

Skadden partner Joseph Barloon, former Jones Day partner Brett Shumate and former Wilmer partner Jeffrey Kessler, among ...

AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...

Shares of top US drugmakers Pfizer, Merck, Eli Lilly, Bristol Myers and Johnson & Johnson all dipped during the cabinet ...

A gas fire “of uncertain origin” caused the June 29 explosion that killed one person, hospitalized two others and displaced ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...